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ABSTRACT

Diabetes mellitus (hereinafter referred to as diabetes) is a serious health
concern affecting the daily lives of many Americans in both clinical and financial
aspects. Diabetes affects approximately 26 million people of all ages in the United
States, and the total estimated medical costs of diagnosed diabetes in the U.S. in
2012 exceeded $200 billion. To obtain better health outcomes, prevent
complications, and reduce unnecessary costs, some health insurance plans
encourage patients to enroll in diabetes management programs that monitor
patient's health status more closely and assist in the adoption of healthy behaviors
and habits. The aims of this study are to compare medication adherence rates and
total healthcare cost among patients participating in a Diabetes Care Management
Incentive Program offered by a commercial health insurer with usual care.
This study was performed using a retrospective cohort study design;
subjects were insurance plan members with diabetes using metformin-containing
medications. Logistic regression analyses were performed to measure the degree of
association between intervention status (i.e. participation in the diabetes incentive
program) and adherence rates. The adjusted odds ratio with 95% confidence
intervals were reported as the measure of effect. For the total healthcare cost
analysis, the Mann-Whitney U test was utilized to evaluate differences between the
median intervention and non-intervention cost values.
Odds ratios for rates of achieving medication possession ratio (MPR) of
0.80 or greater among the intervention group as compared with the nonintervention groups were 0.966 (95% CI: 0.739 - 1.264) in the bivariate logistic
regression model, 0.995 (95% CI: 0.755 -1.312) in the full logistic regression

model, and 1.008 (95% CI: 0.765 - 1.328) in the fitted logistic regression model.
Additionally, the mean annual total healthcare cost was $8,827.01 ($735.58 per
month) in the intervention group and $10,096.53 ($841.38 per month) in the nonintervention group), yet the difference was not statistically significant (p = 0.2327).
Study results indicate that the medication adherence rates among patients
using metformin-containing medications were similar between members who were
enrolled in the diabetes management program and members who were not enrolled
in the program. However, members participating in the program incurred
approximately $2,200 less in annual total healthcare cost.
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PREFACE
The standard format was used in preparation of this thesis.
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CHAPTER 1

BACKGROUND

Diabetes mellitus (hereinafter referred to as diabetes) is a serious health
concern affecting the daily lives of many Americans. Diabetes affects
approximately 25.8 million people of all ages in the United States, and the affected
number is projected to increase due to an increase in the number of older
Americans and increase in the prevalence of obesity due to westernized diets and
sedentary lifestyles.1-2
Diabetes is an acute and chronic disease caused by high blood glucose
level requiring continuous monitoring and management. There are two major types
of diabetes: Type 1 and Type 2. Type 1 diabetes, which accounts for
approximately 5 to 10% of all diabetes cases, is caused by absolute insulin
deficiency and is treated by exogenous insulin.3 Type 2 diabetes, the most common
type of diabetes, accounting for approximately 90 to 95% of all cases, is
characterized by insulin sensitivity and insulin secretion defects.4 People with type
2 diabetes have various treatment options including oral hypoglycemic agents and
insulin. Among patients with type 2 diabetes, approximately 24% do not recognize
they have diabetes.4
The total estimated medical costs of diagnosed diabetes in the U.S. in 2012
was $245 billion, a 40% increase from $174 billion in 2007, and the cost will
continue to increase due to an increasing number of patients having diabetes.5This
expenditure includes both direct medical costs such as hospital inpatient care,
prescription medications, physician office visits, and residential/nursing facility
1

stays, and indirect medical costs such as reduced productivity and inability to
work.5
To obtain better health outcomes, prevent complications, and reduce
unnecessary costs, some health insurance plans encourage patients to enroll in
diabetes management programs. Typical components of diabetes management
programs, include periodic physical examinations, appointment reminders by
health care personnel, patient education to enhance self-management skills and
encourage healthful behaviors such as daily exercises and eating more fresh fruits
and vegetables, and laboratory examinations including cholesterol levels, liver
function tests, and blood glucose levels.
Research evaluating the effectiveness of diabetes management programs
have assessed clinical outcomes such as decrease in hemoglobin A1c level,
cardiovascular risks, and foot infection risks to determine effectiveness.6-7For
example, the Asheville Project, a disease management program, started in 1996 by
the city of Asheville, North Carolina.8The program enrolled patients with asthma,
hypertension, hypercholesterolemia and diabetes and provided educational and
personal disease management services for employees of the city of Asheville.8
Participants with diabetes experienced improved hemoglobin A1C levels, lower
total health care costs, and fewer sick days.8A long term follow-up study
determined that approximately 50% of participants experienced decreases in mean
hemoglobin A1c and lipid level at each follow-ups.9Another study evaluated the
association between a health maintenance organization (HMO) sponsored diabetes
management program and hemoglobin A1c level and determined that individuals
participating in the diabetes management program improved short-term glycemic
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control significantly.10 According to the study, mean hemoglobin A1c of patients
decreased from 8.51to 7.41 after 3 months of follow-up.10
However, there is a lack of study of the cost effectiveness of diabetes
management programs, due to the difficulty and complexity in describing
economic outcomes.11 It is often difficult to gather all of the diabetes-related direct
and indirect costs, and as a result, less is known about the disease management
programs' impact on medical expenditure for patients with diabetes.1112

Nonetheless,results of one study suggested that intensified diabetes care

management activities increased diabetes medication adherence by 4%, and
another study determined that patients with diabetes that participated in the
Asheville Project experienced a decrease in total mean direct medical costs of
$1,200 to $1,872 per year compared to patients with diabetes who did not
participate in the intervention. Additionally, the Asheville Project saved an
employer group approximately $18,000 per year.9,13 However, not all diabetes
management programs have a favorable impact on financial outcomes with
incremental medical costs ranging from -$16,996 to $3,305 per patient per year.14
This current study will assess the associations between enrollment in a
diabetes management program provided by a commercial insurance plan and
health expenditure and diabetes medication adherence rate. Diabetes management
programs are known for assisting participants to achieve better diabetes medication
adherence and ,eventually, better health outcomes, thus insurance plans can
possibly reduce spending through better diabetes medication adherence and better
health outcomes: less hospitalization, less diabetes complications and increase in
work productivity.15-16Poor medication adherence causes approximately 125,000
deaths due to increase in morbidity in hospitalizations.17 Furthermore, poor
3

medication adherence costs the U.S. health care system up to $289 billion
annually.17In addition, cost burdens of diabetes are large with medication costs,
frequent hospital visits, and possible hospitalizations, as noted above.
The diabetes incentive program evaluated in our study aims to improve
diabetes-related care and decrease medical expenses due to diabetes and diabetesrelated complications. The program provides participants' diabetes medications
free of charge if they agree to participate in an annual physical examination,
complete a hemoglobin A1c blood test at least twice a year, have an annual low
density lipoprotein cholesterol test, participate in case coordination led by case
managers, and personalized support and educational sessions provided by a
registered nurses and dieticians.
This study will help in fulfilling pharmacoeconomic-research demands
about diabetes management programs and contribute to the development of more
economically efficient diabetes management programs. The study's hypothesis is
that the members enrolled in the diabetes management program will achieve higher
medication adherence rate than those who are not enrolled in the diabetes
management program. A secondary hypothesis is that the members enrolled in the
diabetes management program will experience reduced total healthcare
expenditure compared to the members nor enrolled in the diabetes management
program.
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CHAPTER 2

METHOD

This study was a retrospective cohort study, assessing the association
between a diabetes management program and its effects on participants' medication
adherence and medical costs. The data were provided by a commercial health
insurer, and included members' medical diagnoses, basic demographics, medical
and pharmacy spending information, and health care procedures. The dataset
includes members who enrolled in the Diabetes Incentive Program (intervention)
and who did not enroll (non-intervention) between January 1st of 2008 and May
31st of 2010. Through the participation of the Diabetes Incentive Program,
members were able to obtain the following health management services: (a)
participate in care coordination with a case manager, (b) have an annual physical
examination, (c) have a hemoglobin A1c blood test at least twice annually, (d)
have a low density lipoprotein cholesterol (LDL-C) test at least once annually, and
(e) attend dietary, lifestyle, and diabetes management educational sessions led by
registered nurses and dieticians If members participated in all of these services,
they received a substantial to full price discounts on their hypoglycemic
prescriptions.
In order to be included in the study population, patients had to be aged 18
years or above and have at least 1 ICD-9-CM (The International Classification of
Diseases, Ninth Revision, Clinical Modification) for diabetes, and at least 1 claim
for an anti-diabetic medication during the last 12-month period of continuous
enrollment (365 days). In this study, only metformin and metformin-containing
combination medications were considered as metformin is the first line oral
5

hypoglycemic agent.18 In addition, patients with diabetes generally utilize
metformin continuously, whereas other diabetes medications such as sulfonylurea
and dipeptidyl peptidase-4 (DPP-4) inhibitors are used as add-on therapies. All
possible metformin-containing combination medications on the market were
included in this study (see Appendix A). To assist in identifying all metformincontaining medications, drug information databases Clinical Pharmarmacology®
and Micromedex® were used.
Patient gender, comorbidities, insulin usage, the total number of
medications used (diabetes and non-diabetes), and age group were defined as
categorical variables. Cardiovascular diseases, pulmonary diseases, and mental
health disorders were the examined comorbidities, and were determined based on
published ICD 9 code sets (see Appendix B,C,D,E,F,G). The total number of
dispensed medications represented the number of different prescription
medications dispensed to these patients for 12 months. Quartiles of frequency
distribution were used to categorize the total number of dispensed medications:
group 1 (1-7 total medications), group 2 (8-13 total medications), group 3 (14-17
total medications) and group 4 (18 and more total medications). Age was described
as a continuous variable; and then categorized according to groupings that
generally reflected older (age of 65 and above), middle aged (age of 50 to 64), and
young adult patients (age of 18 to 49).

Statistical analysis (Medication adherence)
The first analysis assessed the relationship between enrollment in the
Diabetes Incentive Program and the diabetes medication adherence rate. To
measure the medication adherence rate, the study utilized MPR (Medication
6

Possession Ratio), calculated as the sum of the days supply for all relevant
medication dispensing during the measurement period, divided by the number of
days elapsed during the period.19-21This study evaluated MPR based on 12-month
elapsed period of enrollment in the diabetes management program. If a patient had
an MPR of equal to or higher than 0.80 (80%), the patient was classified as being
adherent to the diabetes medication. For these analyses, we focused on dispensings
of metformin-containing medications, regardless of different strengths, dosage
forms, and releasing forms.
Chi-square tests were performed to determine if there were differences in
the percentage of patients classified as adherent and those enrolled and not enrolled
in the Diabetes Incentive program. Multivariate logistic regression analyses were
performed to determine the association between the enrollment in the Diabetes
Incentive Program and the MPR (dependent variable), controlling for other
independent variables including patient age group, gender, comorbidities, insulin
usage, and the total number of medications dispensed. Independent variables were
assessed for co-linearity, and the Hosmer-Lemeshow goodness of fit test was
performed to assess the calibration of the final model. The adjusted odds ratio with
95% confidence intervals were reported as the measure of effect.

Statistical analysis (Healthcare cost)
The second analysis assessed differences in health care cost among
patients with diagnosed diabetes participating in the Diabetes Incentive Program
and those receiving usual care. We determined health expenditures for the range of
utilized health services, including hospitalization costs and diabetes medication
costs of participants who were enrolled in the Diabetes Incentive Program and for
7

those who were not enrolled in the Diabetes Incentive Program. Costs were
defined as the amount paid by the health insurance plan, which does not include
copayments made by patients. Costs included both diabetes-related and nondiabetes related physician visits, hospitalizations, laboratory tests, and prescription
drug costs. Total healthcare expenditures during the 12 month timeframe was
compared between intervention and non-intervention groups.
The distribution of costs was analyzed prior to determining the appropriate
statistical test for evaluating group differences in healthcare spending. Mean costs
by group were reported, and where data were skewed, a log transformation was
performed. The student's t-test was used to assess mean differences in cost, and
given the skewed nature of the data, median-based tests were also performed to
assess the statistical significance of these cost differences.
These costs analyses included the same independent variables from the
adherence analysis: age, gender, comorbidities, insulin usage, and total number of
medications dispensed. To evaluate the statistical significance of differences in
these baseline characteristics and health expenditure, the students t-test was
utilized. The Mann-Whitney U test was also utilized to evaluate differences
between the median intervention and non-intervention cost values.
Data analysis was performed using SAS (version 9.3).
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CHAPTER 3

RESULTS

A total of 284 intervention members and 5,528 non-intervention members
met all the cohort selection criteria (see Figure A). The intervention group had a
mean age of 54.06 years (SD=9.50) and the non-intervention group had a mean age
of 54.59 years (SD=8.59) (see Table 1).About one-quarter in the intervention
group (26.06%, n=74) and the non-intervention group (25.92%, n=1,433) were
between 18-49 years of age. The frequency of the population aged50-64 years was
61.97% in the intervention group and 64.36%, while the frequency of population
who is 65 years and above was 11.97% in the intervention group and 9.71% in the
non-intervention group. Percent differences across age groups were not statistically
significant (p=0.4396).
The frequency of males was 61.27% in the intervention group and 61.09%
in the non-intervention group, and the frequency of females was 38.73% in the
intervention group and 38.91% in the non-intervention group. Although it was not
a statistically significant difference, the frequency of insulin use was 39.79% in the
intervention group and 35.42% in the non-intervention group (p=0.952).
Differences in the prevalence of the comorbidities of respiratory disease and
cardiovascular disease were statistically significant between the two groups
(p=0.0409 Respiratory disease, p=0.0026 Cardiovascular disease); 7.04% of the
intervention group and 10.89% of the non-intervention group had a respiratory
disease, while 7.04% of the intervention group and 13.17% of the non-intervention
group had a documentation of cardiovascular disease, respectively. Additionally,
9

15.49% of the intervention group and 14.35% of the non-intervention group had a
mental health disorder, although this difference was not statistically significant
(p=0.5920).The frequency of thoseusing1 to 7 total medications was 25.00% in the
intervention group and 20.98% in the non-intervention group, and the frequency of
those using 8 to 13 total medications was 29.58% in the intervention group and
31.35% in the non-intervention group. The frequency of those using 14 to 17 total
medications was 16.90% in the intervention group and 16.75% in the nonintervention group, and the frequency of those using more than 18 total
medications was 28.52% in the intervention group and 30.92% in the nonintervention group. The frequency based on the number of total medications was
not statistically significant, and both intervention and non-intervention patients
appeared to utilize a similar number of medications during the measurement period.

Results (Medication adherence)
Result assessing medication adherence revealed that 72.89% of the
intervention group and 73.55% of the non-intervention group achieved MPR of
0.80 or greater, although this difference was not statistically significant (p=0.8042).
Mean ages of the subgroups who achieved MPR greater than or equal to 0.80 and
who did not achieve MPR of 0.80 or higher were 55.24 and 52.64, respectively
(p=<0.0001, SD=8.34 and 9.15) (see Table 2).Adherence rates increased with age:
64.90% of the subgroup aged 18-49 years, 75.87% of the subgroup aged 50-64
years old, and 80.91% of the subgroup aged 65 years old and above achieved MPR
greater than or equal to 0.80 (p=<0.0001). Although this finding was not
statistically significant (p=0.2646), 74.04% of male and 72.71% of female
achieved MPR greater than or equal to 0.80. Patients utilizing higher numbers of
10

medications were more frequently classified as adherent to the diabetes
medications: 60.60% of the subgroup using 1 to 7 total medications, 70.17% of the
subgroup using 8 to 13 total medications, 77.31% of the subgroup using 14 to 17
total medications, and 83.74% of the subgroup using more than 18 total
medications achieved MPR greater than or equal to 0.80 (p=<0.0001).Among
patients with documented mental health disorders, 74.17% of the subgroup without
mental health disorders and 69.38% of subgroup with mental health disorders
achieved MPR greater than or equal to 0.80 (p=0.0037). For cardiovascular disease,
72.87% of the subgroup without cardiovascular disease and 77.64% of the
subgroup with cardiovascular disease achieved MPR greater than or equal to 0.80
(p=0.0058).
Being enrolled in the intervention was not associated with higher
medication adherence rate in the bivariate logistic regression analysis(see Table 3).
Both the intervention group and the non-intervention group had a similar
likelihood of achieving MPR of 0.80 (OR= 0.966; 95% CI: 0.739 - 1.264).
Increasing age was associated with increased likelihood of achieving MPR of 0.80
or greater. The subgroup aged 50 to 64 years was 39% more likely to have been
adherent (OR 1.393; 95% CI: 1.236 - 1.570), while the subgroup aged65 years and
above was 59% more likely to have been adherent (OR 1.590; 95% CI: 1.279 1.975). Female members had similar likelihood of achieving MPR of 0.80 or
greater as the male members, with an odds ratio of 0.934 (95% CI: 0.830 - 1.053).
If members were taking more medications, they were more likely to achieve MPR
of 0.80 or greater. The subgroup taking 8 to 13 total medications was 22% less
likely to have been adherent (OR 0.782; 95% CI: 0.691 - 0.885). The subgroup
taking 14 to 17 total medications was 27% more likely to have been adherent (OR
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1.276; 95% CI: 1.084 - 1.501) while the subgroup taking 18 or more medications
was 131% more likely to have been adherent (OR 2.317; 95% CI: 2.010 - 2.672).
Based on the saturated logistic regression model, the impact of
intervention group status was also not significantly associated with medication
adherence (see Table 4). The intervention group had similar likelihood of
achieving MPR of 0.80 or greater as the non-intervention group, with an adjusted
odds ratio of 0.995 (95% CI: 0.755 - 1.312).Similar to results from the bivariate
logistic regression analysis, if members were older, they were more likely to
achieve MPR of 0.80 or greater.
The patient subgroup aged 50 to 64 years was 46% more likely to have
been adherent (OR 1.467; 95% CI: 1.283 - 1.679), while the subgroup aged 65
years and above was 89% more likely to have been adherent (OR 1.897; 95% CI:
1.488 - 2.418), (p=<0.0001). Female members had similar likelihood of achieving
MPR of 0.80 or greater as the male members, with an adjusted odds ratio of 0.909
(95% CI: 0.802 - 1.030). Also, similar to results from the bivariate logistic
regression analysis, if members were taking more medications, they were more
likely to achieve MPR of 0.80 or greater. The subgroup taking 8 to 13 total
medications was 49% more likely to be adherent (OR1.493; 95% CI:1.279 1.744).The subgroup taking 14 to 17 total medications was 119% more likely to
have been adherent (OR 2.194; 95% CI: 1.810 - 2.659), while the subgroup taking
18 or more medications was 248% more likely to have been adherent (OR 3.480;
95% CI:2.905 - 4.170),(p=<0.0001).
In the fitted multiple logistic regression model, the impact of intervention
group status was not statistically significant (see Table 5). The intervention group
had similar likelihood of achieving MPR of 0.80 or greater as the non-intervention
12

group, with an adjusted odds ratio of 1.008 (95% CI: 0.765 - 1.328).Older
members were more likely to achieve MPR of 0.80 or greater. Those aged 50 to 64
years were 45% more likely to have been adherent (OR 1.458;95% CI: 1.276 1.667), and individuals aged 65 years and above were 86% more likely to be
adherent (OR 1.861; 95% CI: 1.464 - 2.365), (p=<0.0001). If members were taking
more medications, they were more likely to achieve MPR of 0.80 or greater. The
subgroup taking 8 to 13 total medications was 49% more likely to have been
adherent (OR 1.492; 95% CI: 1.279 - 1.742). The subgroup taking 14 to 17 total
medications was more than twice as likely to have been adherent (OR 2.161; 95%
CI: 1.784 - 2.618), while the subgroup taking 18 or more total medications was
more than 3 times as likely to have been adherent (OR 3.354; 95% CI: 2.809 4.005), (p=<0.0001). Good model calibration was shown by the HosmerLemeshow goodness of fit test with a p-value of 0.3768, implying good matching
between expected and observed event rates in population's subgroup.

Results (Healthcare cost)
Although it was not statistically significant (p=0.2327), The mean annual
per patient total healthcare cost, including both pharmacy-related cost and medical
cost, was $8,827.01 ($735.58 per month) in the intervention group and $10,096.53
($841.38 per month) in the non-intervention group (see Table 6). The mean annual
per patient pharmacy-related cost was $2,904.92 ($242.08 per month) in the
intervention group and $2,655.21 ($221.27 per month) in the non-intervention
group (p=0.2065), and the mean medical cost was $5,922.08 ($493.51) in the
intervention group and $7,438.93 ($619.91 per month) in the non-intervention
group (p=0.1363).
13

The mean total healthcare costs of male and female patients in the
intervention group were $7,761.1 and $10,513.0 respectively, and the mean total
healthcare costs of males and females in the non-intervention group were $9,785.9
and $10,583.1, respectively(see Table 7). Analysis of age groups revealed a mean
total healthcare cost of intervention and non-intervention population aged 18 to 49
years to be $7,015.2 and $8,244.1, respectively. For those who were 50 to 64 years
old, intervention group had the mean total healthcare costs of $9,117.0, and nonintervention group had the mean total healthcare costs of $10,551.7. The mean
total healthcare costs of intervention and non-intervention population who are 65
years old and above were $11,269.4 and $12,028.0, respectively. All the mean total
healthcare cost results based on different age groups were not statistically
significant. For the total medication counts, the mean total healthcare costs of
intervention and non-intervention members who are taking 1 to 7 total medications
were $4,495.2 and $6,261.6, respectively. For those who are taking8 to 13 total
medications, intervention group had the mean total healthcare costs of $6,836.4,
and non-intervention group had the mean total healthcare costs of $7,661.0. The
mean total healthcare costs of intervention and non-intervention members who are
taking 14 to 17 total medications were $7,689.9 and $9,380.5, respectively. The
mean total healthcare costs of intervention and non-intervention members who are
taking 18 or more total medications were $15,362.3 and $15,548.9, respectively.
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CHAPTER 4

DISCUSSION

Diabetes mellitus is a serious obstacle for the United States health care
system in both clinical and financial terms. Affecting approximately 8.3% of the
U.S. population, it is the seventh leading cause of death, and is a major cause of
cardiovascular diseases, the first leading cause of death in the U.S.1,22

Discussion (Medication adherence)
The first goal of this study was to determine whether the participation in a
Diabetes Incentive Program provided by a commercial insurer affects the diabetes
medication adherence rate. Contrary to the study hypothesis, members who were
enrolled in the diabetes management program did not achieve higher MPR of 0.80
or greater than members who were not enrolled in the diabetes management
program. Odds ratios for rates of achieving MPR of 0.80 or greater among the
intervention group as compared with the non-intervention groups were 0.966 (95%
CI: 0.739 - 1.264) in the bivariate logistic regression model, 0.995 (95% CI: 0.755
- 1.312) in the full logistic regression model, and 1.008 (95% CI: 0.765 - 1.328) in
fitted logistic regression model. All three logistic regression analyses provided
consistent results and demonstrated that the medication adherence rates with
metformin-containing medications between members who were enrolled in the
diabetes management program and members who were not enrolled in the diabetes
management program were similar.
Medication adherence rates, however, were associated with age, total
medication dispensings, and presence of mental health disorders. Older patients
15

were more likely to achieve MPR of 0.80 or greater than younger patients. The
subgroup who were 50 to 64 years old had odds ratio of 1.458 (95% CI: 1.276 1.667) in the fitted logistic regression model. The subgroup who were 65 years old
and above had odds ratio of 1.861 (95% CI: 1.464 -2.365) in the fitted logistic
regression model. Based on these consistent results, those older than 65 years old
and above had approximately twice the likelihood of achieving MPR of 0.80 or
greater than group that were 18 to 49 years old, indicating that older patients may
manage their health conditions more diligently due to the possibility of having
more comorbidities and health issues.
Those using more medications were more likely to achieve MPR of 0.80
or greater than those using less medications. All three logistic regression analyses
provided consistent results of increasing likelihood of achieving MPR of 0.80 or
greater if total medication counts increase. The subgroup using 18 or more
medications had an odds ratio of 3.354 (95% CI: 2.809 - 4.005) in the fitted
logistic regression model. Based on these results, subgroup using more 18 or more
medications had approximately three times the likelihood of achieving MPR of
0.80 or greater than population using 1 to 7 medications. These results reveal that
members taking more medications were more adherent to their medications, which
maybe indicating that members taking more medications regard the activity of
medication intake more seriously due to their possibly less healthy status.
Therefore, the diabetes management program should specifically target younger
members taking less medications to improve their suboptimal medication
adherence and enhance the program's performance.
Among the three comorbidities evaluated, the subgroup having a diagnosis
of a mental health disorder was less likely to achieve MPR of 0.80 or greater than
16

population without a mental health disorder. The population with mental health
disorders had odds ratio of 0.703 (95% CI: 0.595 - 0.831) in the fitted logistic
regression model. All three logistic regression analyses provided consistent results
of decreasing likelihood of achieving MPR of 0.80 or greater if one has a
documented mental health disorder. The presence of respiratory diseases or
cardiovascular diseases did not affect the likelihood of achieving MPR of 0.80 or
greater. The state of depression affects one's medication adherence due to
decreased motivation and willingness. A meta analysis by Grenard et al (2011)
found that depressed patients are 1.76 times more likely to be non-adherent to their
medications compared to patients without depression.23 Therefore, the diabetes
management program should specifically target depressed patients to prevent
patients' disengagement and improve program's performance.
Other independent characteristics including gender were not associated
with medication adherence. The subgroup that used insulin was less likely to
achieve MPR of 0.80 or greater, although this association was not consistent across
the three logistic regression models. In the fitted logistic regression model, the
odds ratio for insulin use was 0.874 (95% CI: 0.769 - 0.993), (p=0.0379). This
result is maybe due to the relationship between diabetes severity and insulin usage.
If diabetes worsens, patients tend to switch to insulin therapy from oral diabetes
medications including metformin.
The results of this study indicate that an incentive-based diabetes
management program did not yield increased rates of medication adherence among
participants when compared with rates among members with diabetes not
participating in the diabetes management program. Medication adherence rates
were similar between the two groups in all three logistic regression statistical tests,
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which indicates that the program likely did not yield clinical benefits as a
consequence of more consistent medication taking. However, medication
adherence rates were already fairly high among all patients included in this study,
suggesting that the opportunity for improvement was limited.

Discussion (Healthcare cost)
The second aim of this study was to determine whether the participation of
a Diabetes Incentive Program provided decreased health expenditures including
both medical and pharmacy-related costs. Although the cost analyses performed
did not reveal statistically significant differences in cost, members who were
enrolled in the diabetes management program had lower total health expenditures
than members who were not enrolled in the diabetes management program. The
mean total healthcare cost, including both pharmacy-related cost and medical cost,
was $8,827.01 ($735.58 per month) in the intervention group and $10,096.53
($841.38 per month) in the non-intervention group. While patients in the diabetes
management program incurred approximately $2,200 less in annual healthcare cost,
cardiovascular and respiratory comorbidities were less prevalent among program
participants.
Total healthcare costs varied across several of the independent variables
evaluated. As expected, older patients were more likely to have higher mean total
healthcare cost than younger patients in both the intervention group and nonintervention group. Female patients were more likely to have higher mean total
healthcare cost than male patients in both the intervention group and nonintervention group. Patients using insulin were more likely to have higher mean
total healthcare cost than population not using any insulin in both intervention
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group and non-intervention group, reflecting the progressed disease status among
these patients. Patients using more medications were more likely to have higher
mean total healthcare cost than population using less numbers of medications in
both intervention group and non-intervention group. Analysis of the relationship
between patient age and total medication dispensings suggested that these two
continuous variables were not highly correlated (Spearman r = 0.179), suggesting
that both increasing age and a greater number of medications used were
independently associated with higher health care expenditure.
As expected, patients with comorbidities (respiratory disease, mental
health disorder, and cardiovascular disease) were more likely to have a higher
mean total healthcare cost than population without comorbidities. When examining
costs across comorbidity categories, the mean total healthcare costs of intervention
and non-intervention population with respiratory diseases were $23,337.4 and
$17,937.7, respectively; the mean total healthcare costs of intervention and nonintervention population with cardiovascular diseases were $24,627.6 and $19,503.9,
respectively. These results reveal that older members with more comorbidities and
more medications prescribed incurred greater total healthcare costs. Based on this
finding, diabetes management program should consider focusing on older members
with comorbidities and use of a greater number of medications to reduce total
healthcare costs through the programs components.

Discussion (Limitations)
There were several limitations in this study. First, intervention and nonintervention groups were fundamentally different, and this difference prevented us
to confirm that the diabetes management program solely contributed to
19

intervention group's lower total healthcare costs. In the intervention group,
subgroups with respiratory diseases and cardiovascular diseases were 7.04% and
7.04%, and in non-intervention group, subgroups with respiratory diseases and
cardiovascular diseases were 10.89% and 13.17% (p=0.0409 and 0.0026). The
intervention group was generally healthier than the non-intervention group.
Additionally, there were no comparisons to medication adherence rates or
cost in prior months. Without having access to previous data, the study was unable
to determine if the intervention was progressively improving members' medication
adherence and costs. It is possible that the intervention may have provided greater
gains or losses in medication adherence and costs from the previous year than the
non-intervention group, yet we were not able to evaluate the progressive impacts
on the diabetes management program. Moreover, the study's 12-month evaluation
period may have been too limited to measure the intervention's impact on
medication adherence and total healthcare costs.
Furthermore, the study was unable to determine the temporal relationships
between examined variables due to the short time period for follow up. In this case,
there is a possibility that some members could have been diagnosed with a
cardiovascular disease on the last day of their enrollment periods of 12 months and
would have been labeled as cardiovascular patients for the entire study period. This
limitation could falsely increase cost burdens of participants with some
comorbidities. An additional limitation is that the study only considered metformin
and metformin-containing medications for adherence to diabetes medication. As
metformin is usually the first line oral therapy agent for diabetes mellitus and nonmetformin medications are add-on therapies. Users of other oral diabetes
medications such as sulfonylureas, DPP-4 inhibitors, or thiazolidinediones were
20

excluded in this study. The medication adherence rates of this study, therefore,
could over-represent healthier populations, and overall oral diabetes medication
adherence rates may be different from the result.
Additionally, another study limitation is that the administrative data source
only included information about paid claims and excluded any procedure or
medication that were paid out-of-pocket. The study, also, assumed that members
consumed the dispensed medications, but compliance to dispensed medications
was not measured or assessed. There is a possibility that the study misclassified
members that did not take medications that had been dispensed as adherent to their
medications. Also, the data source did not include information about patient race,
ethnicity, and socioeconomic factors, which may have been associated with both
the independent variables studied and the outcomes of medication adherence, and
total healthcare cost.
There were cost outliers, affecting average medical, pharmacy, and total
healthcare cost values. The highest cost for the non-intervention group was
$345,862.33 and for the intervention group was $166,091.36. To evaluate the two
groups not affected by the outliers, a median-based test was performed in the
statistical analysis. Due to these outliers in the cost analysis, standard deviations
became higher than mean values, and analysis results turned out to be statistically
not significant.
In addition, the lack of randomization may not avoid impacts from
unidentified or unseen biases or confounders. Also, members deciding to enter the
diabetes management program could have been more careful about their own
health, and this may have possibly led to a selection bias.

21

CHAPTER 5

CONCLUSION

Results of this study found that a Diabetes Incentive Program did not
improve participants' medication adherence rates. Although not statistically
significant, participation was associated with reduced total healthcare costs. Older
participants and those taking more medications were associated with greater
adherence to diabetes medications but incurred greater total healthcare costs.
Certain comorbidities such as mental health disorders also affected medication
adherence and total healthcare costs adversely. Further studies about the Diabetes
Incentive Program should be performed to evaluate changes in rates of medication
adherence and total healthcare costs over time.
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Table 1: Selected Characteristics of Patients Participating in the Diabetes
Incentive Program and Patients in the Comparison Group (Intervention vs.
Nonintervention)
Variable

N
%
54.056 [9.50]

Non-intervention
(N=5,528)
N
%
54.585 [8.59]

74
176
34

26.06
61.97
11.97

1,433
3,558
537

25.92
64.36
9.71

0.4396

Gender
Male
Female

174
110

61.27
38.73

3,377
2,151

61.09
38.91

0.952

Insulin
No
Yes

171
113

60.21
39.79

3,570
1,958

64.58
35.42

0.1338

25.00
29.58
16.90
28.52

1,160
1,733
926
1,709

20.98
31.35
16.75
30.92

0.4178

Comorbidity (Respiratory diseases)
No
264
92.96
Yes
20
7.04

4,919
601

89.11
10.89

0.0409

Comorbidity (Mental health disorders)
No
240
84.51
Yes
44
15.49

4,728
792

85.65
14.35

0.5920

Comorbidity (Cardiovascular diseases)
No
264
92.96
Yes
20
7.04

4,793
727

86.83
13.17

0.0026

Mean [SD] age
Age group
18-49
50-64
65+

Intervention (N=284)

Total Medication Counts
1-7
71
8-13
84
14-17
48
18+
81
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P value

0.3145

Table 2: Association Between Selected Characteristics of Study Patients and
Diabetes Medication Adherence (Medication Possession Ratio (MPR)< 80 vs.
MPR >= 80)
Variable
Mean [SD] age

MPR < 80
N
%
52.64 [9.15]

MPR >= 80
N
%
55.24 [8.34]

Age group
18-49
50-64
65+

529
901
109

35.10
24.13
19.09

978
2,833
462

64.90
75.87
80.91

<0.0001

Gender
Male
Female

922
617

25.96
27.29

2,629
1,644

74.04
72.71

0.2646

Insulin
No
Yes

991
548

26.49
26.46

2,750
1,523

73.51
73.54

0.9805

39.40
29.83
22.69
16.26

746
1,275
753
1,499

60.60
70.17
77.31
83.74

<0.0001

Comorbidity (Respiratory diseases)
No
1,368
26.39
Yes
171
27.54

3,815
450

73.61
72.46

0.5423

Comorbidity (Mental health disorders)
No
1,283
25.83
Yes
256
30.62

3,685
580

74.17
69.38

0.0037

Comorbidity (Cardiovascular diseases)
No
1,372
27.13
Yes
167
22.36

3,685
580

72.87
77.64

0.0058

Intervention
No
Yes

4,066
207

73.55
72.89

0.8042

Total Medication Counts
1-7
485
8-13
542
14-17
221
18+
291

1,462
77

26.45
27.11
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P value
<0.0001

Table 3: Bivariate Logistic Regression Analysis Assessing the Likelihood of
Diabetes Medication Adherence According to Selected Patient Characteristics
Beta

OR

95 CI%
low

95% CI
High

P value

Age group
18-49
50-64
65+

Ref
0.3315
0.4634

1.393
1.590

1.236
1.279

1.570
1.975

<0.0001
<0.0001

Gender
Male
Female

Ref
-0.0678

0.934

0.830

1.053

0.2647

Insulin
No
Yes

Ref
0.00152

1.002

0.887

1.131

0.9805

0.782
1.276
2.317

0.691
1.084
2.010

0.885
1.501
2.672

<0.0001
0.0034
<0.0001

0.783

1.137

0.5423

Comorbidity (Mental health disorders)
No
ref
Yes
-0.2372
0.789
0.672

0.926

0.0037

Comorbidity (Cardiovascular diseases)
No
ref
Yes
0.2570
1.293
1.077

1.553

0.0059

Intervention
No
Yes

1.264

0.8028

Total Medication Counts
1-7
Ref
8-13
-0.2455
14-17
0.2435
18+
0.8405

Comorbidity (Respiratory diseases)
No
Ref
Yes
-0.0580
0.944

ref
-0.0342

0.966

0.739
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Table 4: Saturated Model Logistic Regression Analysis: Likelihood of
Adherence (Medication Possession Ratio>= 80%) among Selected Patient
Characteristics
Beta

OR

95 CI%
low

95% CI
High

P value

Age group
18-49
50-64
65+

ref
0.3835
0.6401

1.467
1.897

1.283
1.488

1.679
2.418

<0.0001
<0.0001

Gender
Male
Female

ref
-0.0959

0.909

0.802

1.030

0.1329

Insulin
No
Yes

ref
-0.1323

0.876

0.771

0.995

0.0421

1.493
2.194
3.480

1.279
1.810
2.905

1.744
2.659
4.170

<0.0001
<0.0001
<0.0001

0.678

1.004

0.0552

Comorbidity (Mental health disorders)
No
ref
Yes
-0.3248
0.723
0.611

0.855

0.0002

Comorbidity (Cardiovascular diseases)
No
ref
Yes
-0.0946
0.910
0.748

1.106

0.3435

Intervention
No
Yes

1.312

0.9708

Total Medication Counts
1-7
Ref
8-13
0.4011
14-17
0.7855
18+
1.2471

Comorbidity (Respiratory diseases)
No
ref
Yes
-0.1919
0.825

ref
-0.00516

0.995

0.755
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Table5: Fitted Logistic Regression Model with Adjusted Odds Ratio for
Intervention versus Non-Intervention Status as a Predictor of Medication
Adherence (MPR >= 80%), Controlling for Patient Age, Insulin Use, Number
of Rx Utilized, and Presence of a Mental Health Disorder
Beta

OR

95 CI%
low

95% CI
High

P value

Age group
18-49
50-64
65+

Ref
0.3772
0.6211

1.458
1.861

1.276
1.464

1.667
2.365

<0.0001
<0.0001

Insulin
No
Yes

Ref
-0.1350

0.874

0.769

0.993

0.0379

1.492
2.161
3.354

1.279
1.784
2.809

1.742
2.618
4.005

<0.0001
<0.0001
<0.0001

Comorbidity (Mental health disorders)
No
Ref
Yes
-0.3526
0.703

0.595

0.831

<0.0001

Intervention
No
Yes

0.765

1.328

0.9542

Total Medication Counts
1-7
Ref
8-13
0.4004
14-17
0.7705
18+
1.2102

Ref
0.00808

1.008
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Table6: Mean Annual Pharmacy, Medical, and Total Health Care Cost
among Patients Participating in the Diabetes Incentive Program and Patients
in the Comparison Group (Intervention vs. Nonintervention; N=5,812)
INTERVENTION
Mean ($)
Sd

NON-INTERVENTION
Mean ($)
Sd

Pharmacy
PMPM

2,904.92
242.08

2,890.37

2,655.21
221.27

3,265.73

0.2065

Medical
PMPM

5,922.08
493.51

13,303.75

7,438.93
619.91

16,889.93

0.1363

Total
PMPM

8,827.01
735.58

14,246.70

10,096.53
841.38

17,628.76

0.2327

*PMPM = Per Member Per Month
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P value

Table 7: Mean Total Yearly Cost for Selected Characteristics of Patients
Participating in the Diabetes Incentive Program and Patients in the
Comparison Group (Intervention vs. Nonintervention).
INTERVENTION
Mean ($)
Sd

NON-INTERVENTION
Mean ($)
Sd

P value

7,015.2
9,117.0
11,269.4

8,244.1
10,551.7
12,028.0

13,869.2
18,436.3
20,517.6

0.4507
0.3112
0.8314

9,785.9
10,583.1

18,450.7
16,250.3

0.1510
0.9651

8,818.1
12,422.3

15,866.6
20,247.1

0.2911
0.4055

6,261.6
7,661.0
9,380.5
15,548.9

12,887.4
13,806.1
14,393.5
23,261.4

0.2504
0.5867
0.4209
0.9437

9,138.5
17,937.7

15,834.6
27,097.8

0.1518
0.3887

Comorbidity (Mental health disorders)
No
8,302.2
14,837.1
Yes
11,689.8
10,115.7

8,827.1
17,674.5

15,617.6
25,369.5

0.6106
0.1198

Comorbidity (Cardiovascular diseases)
No
7630.0
9920.0
Yes
24627.6
37125.5

8669.6
19503.9

15239.4
26972.4

0.2733
0.4076

Age group
0 (18-49)
1 (50-64)
2 (65+)

8,664.0
16,310.2
12,242.1

Gender
Male
7,761.1
10,070.4
Female
10,513.0
19,008.7
Insulin
No
7,521.2
11,343.2
Yes
10,803.1
17,635.6
Rx number
1-7
4,495.2
4,717.4
8-13
6,836.4
7,214.9
14-17
7,689.9
9,152.6
18+
15,362.3
23,032.0
Comorbidity (Respiratory diseases)
No
7,727.7
9,563.4
Yes
23,337.4
38,971.4
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Figure 1: Population Selection Flowchart
21,153 Initial Cohort

843 Intervention

20,210 Non - Intervention
4,729Enrollment <18Months Excluded

305 Enrollment <18Months Excluded

538

15,481

10<18-Years Old
Excluded

136<18-Years Old
Excluded

528

15,345

232 No DM Diagnosis
Excluded

9,474 No DM Diagnosis
Excluded

296

5,871

12 No DM Med Usage
Excluded

343No DM Med Usage
Excluded

5,528

284
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Appendix A: Metformin-Containing Combination Medications
Actoplus met
Avandamet
Fortamet
Glipizide/Metformin
Glucophage
Glucophage XR
Glumetza
Glyburide/Metformin
Metaglip
Metformin
Metformin ER
Riomet
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Appendix B: ICD-9 Codes to Identify Respiratory Disease
491.0 491.1 491.20 491.21 491.22 491.8 491.9 492.0 492.8 493.00 493.01 493.02
493.10 493.11 493.12 493.20 493.21 493.22 493.81 493.82 493.90 493.91 493.92
496 518.1 518.2
Appendix C: Descriptions of Used ICD-9 Codes to Identify Respiratory
Disease
Code
491
492
493
496
518

Description
Chronic bronchitis
Emphysema
Asthma
Chronic airway obstruction
Other diseases of lung
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Appendix D: ICD-9 Codes to Identify Mental Health Disorder
295.00295.01295.02295.03295.04295.05295.10295.11295.12295.13295.14295152
95.20295.21 295.22295.23295.24295.25295.30295.31
295.32295.33295.34295.35295.40295.41295.42295.43295.44295.45295.50295.51
295.52295.53295.54
295.55295.60295.61295.62295.63295.64295.65295.70295.71295.72295.73295.74
295.75295.80295.81295.82295.83295.84295.85295.90295.91295.92295.93295.94
295.95296.00296.01296.02296.03296.04296.05296.06296.10296.11296.12296.13
296.14296.15296.16296.20296.21296.22296.23296.24296.25296.26296.30296.31
296.32296.33296.34296.35296.36296.40296.41296.42296.43296.44296.45296.46
296.50296.51296.52296.53296.54296.55296.56296.60296.61296.62296.63296.64
296.65296.66296.7296.80296.81296.82296.89296.90296.99297.0297.1297.2297.3
297.8297.9298.0298.1298.2298.3298.4298.8298.9299.00299.01299.10299.11299.
80299.81299.90299.91300.3300.4301.0301.10301.11301.12301.13301.20301.213
01.22301.23301.3301.4301.50301.51301.59301.6301.7301.80301.81301.82301.83
301.84301.89301.9308.0308.1308.2308.3308.4308.9309.0309.1309.21309.22309.
23309.24309.28309.29309.3309.4309.81309.82309.83309.89309.9311312.00312.
01312.02312.03312.10312.11312.12312.13312.20312.21312.22312.23312.30312.
31312.32312.33312.34312.35312.39312.4312.81312.82312.89312.9313.0313.131
3.21313.22313.23313.3313.81313.82313.83313.89313.9314.00314.01314.1314.23
14.8314.9
Appendix E: Descriptions of Used ICD-9 Codes to Identify Mental Health
Disorder
Code
295
296
297
298
299
300
301
308
309
311
312
313
314

Description
Schizophrenia
Episodic mood disorders including manic disorder, depression,
and bipolar disorder
Paranoia
Other nonorganic psychoses
Other psychoses specific to childhood
Neurotic disorder
Personality disorders
Acute reaction of stress
Adjustment reaction
Depressive disorder
Disturbance of conduct (specifically to childhood)
Disturbance of emotions (specifically to childhood)
Hyperkinetic syndrome (specifically to childhood)
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Appendix F: ICD-9 Codes to Identify Cardiovascular Disease
410.00410.01410.02410.10410.11410.12410.20410.21410.22410.30410.31410.32
410.40410.41410.42410.50410.51410.52410.60410.61410.62410.70410.71410.72
410.80410.81410.82410.90410.91410.92411.00411.10411.81411.89412.00413.00
413.10413.90414.00414.01414.02414.03414.04414.05414.06414.07414.10414.11
414.12414.19414.80414.90
Appendix G: Descriptions of Used ICD-9 Codes to Identify Cardiovascular
Disease
Code
410
412
413
414

Description
Acute myocardial infarction
Old myocardial infarction
Angina
Other forms of chronic ischemic heart disease
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